Investor Relations

INVESTORS & MEDIA

Archived Presentations

Jan 11 2021
Regeneron J.P. Morgan 2021 Presentation
Dec 07 2020
Regeneron Oncology Investor Presentation, ASH 2020
Nov 06 2020
Regeneron Corporate Presentation November 2020
Oct 31 2020
Yancopoulos FOCIS Presentation
Sep 29 2020
Regeneron COVID-19 Program Update
Sep 08 2020
ERS 2020 Dupixent TRAVERSE LIBERTY ASTHMA LTS
Aug 12 2020
Corporate Presentation August 2020
Jun 12 2020
2020 Regeneron Shareholder Meeting Presentation
Jun 12 2020
Phase 2 of Pozelimab in PNH
Jun 09 2020
Corporate Presentation June 2020
Jun 01 2020
Trial in Progress - Phase 1-2 for REGN5678 (PSMAxCD28) in mCRPC
Jun 01 2020
Phase 2 of Libtayo in Advanced CSCC - Three-year follow-up
Jun 01 2020
Trial in Progress - Phase 3 for Libtayo in Adjuvant CSCC
Jun 01 2020
Regeneron Oncology Investor Event, ASCO 2020 Presentation
Jun 01 2020
Trial in Progress - Phase 1-2 for REGN5093 (METxMET) in MET-Altered Advanced NSCLC
Jun 01 2020
Phase 2 of Libtayo in Advanced CSCC - Post Hoc Exploratory Analysis
Apr 06 2020
Mar 02 2020
Cowen 40th Annual Healthcare Conference Presentation
Feb 09 2020
Angiogenesis, Exudation, and Degeneration 2020
Nov 07 2019
Regeneron Oncology Strategy
Sep 30 2019
European Society For Medical Oncology (ESMO) Congress 2019
Jun 15 2019
European Hematology Association (EHA) 2019 Annual Meeting
Apr 10 2019
Feb 25 2019
2019 AAAAI Annual Meeting
Feb 09 2019
Angiogenesis, Exudation, and Degeneration 2019
Dec 01 2018
ASH 2018